Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.

Base Genomics logo

Base Genomics joined the BioEscalator in March 2020 after meeting stringent gateway criteria set by the BioEscalator Management Board, who recognised the company’s high growth potential. In 6 months, they have grown from one lab space to two labs and an office with a third lab soon to be occupied. The BioEscalator has been able to support this rapid expansion by providing flexible space and serviced facilities.

Base Genomics was co-founded in 2018 by two Oxford academics Dr Yibin Liu and Dr Chunxiao Song from the Ludwig Institute and OSI’s Entrepreneur in Residence, Oliver Waterhouse, now CEO at Base. Their aim was to focus on developing a simple blood test to detect early-stage cancers.

The underlying DNA methylation detection technology, TAPS, capable long-read DNA sequencing, was developed at the Ludwig Institute for Cancer Research by Drs Liu and Song. Base Genomics’ leadership team is completed by Oxford alumna Dr Vincent Smith and Prof Anna Schuh, who is also Director of Molecular Diagnostics at the University’s Department of Oncology.

The full story can be viewed on the BioEscalator website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.